DRAFT 10 August 2022

- 1 Full title: Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal
 - Vaccines in Adults
- 3 Short title: The Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
- 4 Authors: Jennifer L Farrar, Lana Childs, Mahamoudou Ouattara, Fahmina Akhter, Amadea Britton,
- 5 Tamara Pilishvili, Miwako Kobayashi
- 6 Affiliations: Respiratory Diseases Branch, U.S. Centers for Disease Control and Prevention, Atlanta,
- 7 Georgia, USA; CDC Foundation, Atlanta, Georgia, USA
- 8 Corresponding author: Jennifer L Farrar, <u>ihi4@cdc.gov</u>
- 9

DRAFT 10 August 2022

10 Abstract

11	The 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide
12	vaccine (PPSV23) were previously recommended for adults in the United States. To help inform
13	discussions on recently licensed 15- and 20-valent pneumococcal vaccine use among adults, we
14	conducted a systematic review of PCV13 and PPSV23 efficacy or effectiveness. We conducted a search
15	on PCV13 and PPSV23 efficacy or effectiveness (VE) studies against vaccine type (VT) invasive
16	pneumococcal disease (IPD) and VT-pneumococcal pneumonia in adults. Nineteen studies were
17	included: 13 on VT-IPD (four on PCV13, nine on PPSV23) and eight on VT- pneumococcal pneumonia
18	(three on PCV13, four on PPSV23, one on PCV13 and PPSV23). One randomized-controlled trial (RCT)
19	evaluated PCV13 and observed an efficacy of 75% and 45% against VT-IPD and VT-pneumococcal
20	pneumonia, respectively. No RCTs reported PPSV23 efficacy. PCV13 effectiveness estimates against VT-
21	IPD ranged from 47% to 68%. Pooled PPSV23 effectiveness against VT-IPD was 45% (95% CI: 37%, 51%;
22	I ² =0%). PCV13 VE estimates against VT-pneumonia ranged from –2 to 46%. Pooled PPSV23 VE against
23	VT-pneumococcal pneumonia was 18% (95% CI: -4%, 35%; I ² =0%). Evidence suggests PCV13 and PPSV23
24	are effective against VT-IPD and VT-pneumococcal pneumonia in adults; this was used to inform PCV15
25	and PCV20 policy decisions.
26	
27	Keywords: pneumococcal vaccine, invasive pneumococcal disease, pneumonia, adults, vaccine
28	effectiveness
29	

29

30 Introduction

The bacteria, *Streptococcus pneumoniae*, are responsible for a substantial proportion of disease burden
 in adults, especially among older adults and those with immunocompromising conditions. Invasive
 pneumococcal disease (IPD) incidence among U.S. adults aged ≥65 years was 24 per 100,000 during

DRAFT 10 August 2022

34	2018–2019 (ABCs surveillance), and disease caused by serotype 3, a serotype included in vaccines to
35	prevent pneumococcal disease, is the most common vaccine serotype causing IPD in adults [1, 2]. In a
36	2016 study of U.S. adults hospitalized with radiologically confirmed community-acquired pneumonia,
37	8.2% (n=520) of adults ≥65 years had <i>S. pneumoniae</i> detected by urine antigen; of these, 269 (51.7%)
38	were serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) [2].
39	Until recently, there were two provinces accommended for use in U.S. adults to provent
29	Until recently, there were two pneumococcal vaccines recommended for use in U.S. adults to prevent
40	disease caused by <i>S. pneumoniae</i> . Since 2012, PCV13 has been recommended for use in adults aged ≥19
41	years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks,
42	or cochlear implants. The 23-valent pneumococcal polysaccharide vaccine, PPSV23, has been in use
43	since 1984, and, until recently, was recommended for all adults aged \geq 65 years and adults aged \geq 19
44	years with immunocompromising conditions, functional or anatomic asplenia, or immunocompetent
45	conditions [3]. While studies have shown that PPSV23 is effective against VTIPD, data on effectiveness of
46	PPSV23 against nonbacteremic pneumococcal pneumonia have been inconsistent [4]. In contrast, a
47	large randomized controlled trial (RCT) in adults aged ≥65 years in the Netherlands showed that PCV13
48	is effective against VT-IPD and VT- nonbacteremic pneumococcal pneumonia [5]. Data from this study
49	supported the 2014 recommendation for routine PCV13 use for all adults aged ≥65 years in the United
50	States [4]; however, additional years of data showed that there was limited population-level impact of
51	routine PCV13 use in adults of this age group, likely due to the already realized indirect effects from
52	PCV13 use in children. As a result, in 2019, PCV13 was no longer routinely recommended for adults aged
53	≥65 years without immunocompromising conditions, cerebrospinal fluid leaks, or cochlear implants and
54	instead recommended based on shared clinical decision-making [6].
55	In 2021, two new pneumococcal conjugate vaccines (PCVs) were licensed for use in the United States:

56 15-valent PCV (PCV15) and 20-valent PCV (PCV20) [7, 8]. PCV15 contains all 13 serotypes included in

DRAFT 10 August 2022

57	PCV13 plus serotypes 22F and 33F. In the United States, serotypes 22F and 33F accounted for 15% of IPD
58	in adults aged ≥65 years and 13% of IPD in adults aged 19 through 64 years with certain underlying
59	medical conditions during 2018–2019 [9]. PCV20 contains all serotypes included in PCV13 and PCV15
60	(22F and 33F) as well as serotypes 8, 10A, 11A, 12F, and 15B. In the United States, these additional
61	serotypes accounted for 27% of IPD in adults aged ≥65 years and 28% of IPD in adults with certain
62	underlying medical conditions in 2018–2019 [9]. Phase II/III RCTs for PCV15 [10-12] and PCV20 [13, 14]
63	showed immunogenicity and safety comparable with PCV13 or PPSV23; similar findings were observed
64	for PCV15 use among adults with certain underlying medical conditions [15, 16].
65	A review of PCV13 and PPSV23 effectiveness against clinical outcomes was necessary for a few reasons:
66	first, we expect that PCV15 and PCV20 will have similar effectiveness as PCV13 and PPSV23 and given
67	these new vaccines were licensed based on safety and immunogenicity data only, this review would
68	provide a comprehensive summary of overall pneumococcal vaccine effectiveness against clinical
69	outcomes in adults. Second, PPSV23 was likely to be part of the new recommendations and previous
70	literature found inconsistent evidence regarding PPSV23 effectiveness against non-bacteremic
71	pneumococcal pneumonia. Lastly, PCV13 would be used as a comparator vaccine to the newer higher
72	valent conjugate vaccines under discussion and a full review of PCV13 effectiveness against clinical
73	outcomes was necessary. Therefore, we conducted a systematic review of literature on the efficacy or
74	effectiveness of PCV13 and PPSV23 against VT-IPD and VT-pneumococcal pneumonia in adults to help
75	inform the U.S. Advisory Committee on Immunization Practices' (ACIP) discussions on the use of PCV15
76	and PCV20 among adults.

77 Methods

78 Literature search

DRAFT 10 August 2022

79	In 2019, the Norwegian Public Health Institute (NIPH) conducted a systematic review of literature on
80	pneumococcal vaccine effectiveness in adults for the World Health Organization's Strategic Advisory
81	Group of Experts [17]. We utilized the same search strategy (Appendix 1) and updated the search
82	timeline to update the summary of evidence on pneumococcal vaccine efficacy or effectiveness on
83	pneumococcal disease and mortality in adults.
84	An updated systematic literature search reviewed seven databases [Pubmed, Medline, Embase, CINAHL,
85	Web of Science, Scopus (Web of Science), Epistemonikos, and Cochrane library] for relevant data
86	published during April 2019 to February 2021. All relevant studies from the previous search by NIPH
87	(published during January 2016 to March 2019) were also included in our review. Authors were
88	contacted for additional information whenever possible. The results of all searches were entered into
89	the Covidence systematic review software program [18].
89 90	the Covidence systematic review software program [18]. The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered
90	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered
90 91	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an
90 91 92	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an additional year of search that was performed after the initial review. This search was conducted on April
90 91 92 93 94	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an additional year of search that was performed after the initial review. This search was conducted on April 4, 2022, to identify additional titles published during February 13, 2021, to March 15, 2022, to update
90 91 92 93	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an additional year of search that was performed after the initial review. This search was conducted on April 4, 2022, to identify additional titles published during February 13, 2021, to March 15, 2022, to update the review.
90 91 92 93 94	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an additional year of search that was performed after the initial review. This search was conducted on April 4, 2022, to identify additional titles published during February 13, 2021, to March 15, 2022, to update the review.
90 91 92 93 94 95	The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an additional year of search that was performed after the initial review. This search was conducted on April 4, 2022, to identify additional titles published during February 13, 2021, to March 15, 2022, to update the review. <i>Inclusion and exclusion criteria</i>

98 contained in the vaccines) and VT-pneumococcal pneumonia (defined as pneumonia due to a *S*.

99 *pneumoniae* serotype contained in the vaccines) were included.

DRAFT 10 August 2022

100	We included published RCTs and observational studies (prospective and retrospective comparative
101	cohort studies, case-control or nested case-control studies, indirect cohort studies, screening method
102	studies) from middle- and high-income settings that evaluated direct effects of pneumococcal
103	vaccination on adults (≥16 years). Systematic reviews on PCV13 or PPSV23 efficacy or effectiveness were
104	included to leverage their bibliographies for relevant data. Only English language studies were included.
105	We excluded studies assessing vaccine impact, case reports, case-series, animal studies, modelling
106	studies, health economic evaluations, pneumococcal carriage studies, narrative reviews, studies that
107	only included data on vaccines that are not currently used in the United States (e.g., PCV7, PCV10), ,
108	studies evaluating indirect effects of pediatric pneumococcal vaccination on adult populations, and
109	studies specifically targeting adults with immunocompromising conditions. In addition, because
110	pneumococcal disease epidemiology differs from that in the United States, we excluded studies
111	conducted in low-income settings.
112	Data abstraction and cleaning
113	Titles and abstracts of all citations identified through the literature search were independently screened
114	for relevance and inclusion by two reviewers using Covidence [20]. Articles meeting inclusion through
115	title and abstract screening were then double screened through full-text review. Discordant reviews
116	during title and abstract or full-text review were blindly reviewed for inclusion by an independent third
117	reviewer.
118	Data were independently abstracted by two reviewers for study information (study characteristics,
119	methods, results) using standardized data collection tools and entered into a Microsoft Excel
120	spreadsheet.

DRAFT 10 August 2022

121	Data were also assessed for quality of evidence. Randomized studies were assessed for quality using the
122	Cochrane Risk of Bias 2.0 tool [21], which included consideration of the appropriate generation of
123	random allocation sequences; concealment of the allocation sequences; blinding of participants,
124	healthcare providers, data collectors, and outcome adjudicators; and proportion of patients lost to
125	follow-up. Non-randomized studies were assessed considering the data elements included in the
126	Newcastle-Ottawa scale (NOS) [22] to address potential sources of bias in cohort and case-control
127	studies. Each study was assessed for risk of bias independently by two reviewers. A third reviewer was
128	consulted when there was discordance of overall quality of evidence between the two independent
129	reviewers. Studies with scores ≥7 (out of 9) were deemed high quality/low risk of bias, scores between 4
130	to 6 (out of 9) were deemed medium quality/some risk of bias, and scores \leq 3 were deemed low
131	quality/high risk of bias.
132	Data analysis
133	We conducted descriptive analyses of studies stratified by outcome (VT-IPD or VT- pneumococcal
134	
	pneumonia), vaccine product (PCV13 or PPSV23), and study design (RCT or observational study). When
135	pneumonia), vaccine product (PCV13 or PPSV23), and study design (RCT or observational study). When feasible, we conducted meta-analyses by outcome, product, and study design using Comprehensive
135 136	

138 variable across studies compared with PCV13 studies. To account for waning of vaccine effectiveness

over time [24-29], we limited the PPSV23 analysis to data from individuals who were vaccinated within 5

140 years of assessment. When data were available, we performed sub-analyses by underlying conditions

- and limiting to a younger age group of adults aged 65 through 74 years to account for heterogeneity in
- 142 the study population between observational studies.
- 143 Results

DRAFT 10 August 2022

144 Literature Search

145	The literature search yielded a total of 5,085 articles, 2,499 from the NIPH search that covered titles
146	published during January 2016 to April 2019 and 2,586 from the updated search that covers titles
147	published during April 2019 to March 2022. From the updated search, 1,764 studies were screened for
148	eligibility; 1,525 were excluded during title and abstract screening. During the full-text review, 239
149	articles were screened for eligibility; 229 were excluded. Ten studies were included from the updated
150	searches and nine studies were included from the NIPH search, totaling 19 studies for inclusion in the
151	analysis (Figure 1). Seven studies evaluated PCV13 and 13 evaluated PPSV23; one study evaluated both
152	PCV13 and PPSV23 against VT-pneumococcal pneumonia [30]. Efficacy or effectiveness against VT-IPD
153	was evaluated in 13 studies and against VT-pneumococcal pneumonia in eight studies; two studies
154	evaluated pneumococcal vaccine effectiveness against both VT-IPD and VT-pneumococcal pneumonia
155	(Table) [5, 31].

156 Figure 1. PRISMA Study flow diagram

DRAFT 10 August 2022

158 Table. Characteristics of Included Pneumococcal Vaccine Effectiveness Studies

Author and publication year	Country	Population	Study Design	Study Period	Outcome	VE (95% CI)**	Study Quality
	I		PCV13		I		
Bonten		Dutch pneumococcal	Randomized Controlled Trial	2008 –	VT- IPD	75% (41, 91)	
2015*	Netherlands	vaccine-naïve, community- dwelling adults ≥65 years	(CAPiTA)	2013	Non-invasive non- bacteremic VT-CAP	45% (14, 65)	High***
Heo 2022	South Korea	Hospitalized adults ≥65 years	Test-negative	2015 - 2017	PCV-13-type community- acquired pneumonia	41% (-104, 83)	High
Lewis 2019*	US	Kaiser Permanente Northern California members with no record of prior receipt of PPSV23, adults ≥65 years	Cohort study	2014 – 2018	VT- IPD	68% (38, 84)	High

McLaughlin 2018*	US	Inpatient adults ≥65 years	Test-negative	2013 – 2016	Non-bacteremic VT-pneumococcal pneumonia	68% (-6, 90)	High
Pilishvili 2018	US	Active Bacterial Core Surveillance (ABCs) IPD cases, adults ≥65 years	Case-control; controls identified using ReferenceUSAGov	2015 - 2017	PCV13-type + 6C IPD	59% (11, 81)	High
Pilishvili 2018	US	Active Bacterial Core Surveillance (ABCs) IPD cases, adults ≥65 years	Case-control; controls identified as Medicare beneficiaries with no record of IPD or pneumonia	2015 – 2016	PCV13-type + 6C IPD	47% (4, 71)	High
Prato 2018	Italy	Inpatient and outpatient adults ≥65 years	Test-negative	2013 - 2015	VT-pneumococcal pneumonia	38% (-132, 89)	Low
			PPSV23				
Andrews 2012	UK	Adults ≥65 years	Indirect cohort	2003 - 2010	VT-IPD	48% (32, 60)	Medium

Chandler 2022	US	Inpatient adults	Test-negative	2014 - 2017	VT-pneumococcal pneumonia	2% (-52, 37)	High
Djennad 2018	UK	Adults ≥65 years	Indirect cohort	2012 - 2016	VT-IPD	41% (23, 54)	High
Dominguez 2005	Spain	Adults ≥65 years	Case-control; hospital controls	2001 - 2002	VT-IPD	64% (31, 82)	Medium
Gutiérrez - Rodriguez 2014	Spain	Adults ≥60 years	Indirect cohort	2008 - 2011	VT-IPD	44% (19, 62)	High
Heo 2022	South Korea	Hospitalized adults ≥65 years	Test-negative	2015 - 2017	VT-pneumococcal pneumonia	6% (-74, 50)	High
Kim 2019	South Korea	Adults ≥65 years	Case-control	2013 - 2015	VT-IPD VT- non bacteremic pneumococcal pneumonia	42% (-2, 67) -2% (-40, 26)	High
Lawrence 2020	England	Adults ≥16 years	Case-control	2013 – 2018	VT- pneumococcal pneumonia	46% (5, 69)	Medium

					(PPSV23 non-		
					PCV13 serotypes)		
Perniciaro 2021	Germany	Adults ≥60 years (German National Reference Center for Streptococci (GNRCS))	Indirect cohort	2018 – 2019	VT-IPD (PPSV23 non-PCV13 serotypes)	35% (-14, 65)	High
Rudnick 2013	Canada	Adults ≥65 years	Indirect cohort	1995 - 2011	VT-IPD	41% (21, 56)	Medium
Shimbashi 2020	Japan	Adults ≥20 years Adults ≥65 years	Indirect cohort	2013 - 2017	VT-IPD	39.3% (-2.9, 64.2) 39.4% (-6.1, 65.3)	Medium
Su 2021	Taiwan	Adults ≥75 years	Indirect cohort Screening method	2008 –	VT-IPD	74% (39, 89) 43.4% (34.4, 51.2)	High
Suzuki 2017	Japan	Adults ≥65 years	Test- negative	2011 - 2014	VT- pneumococcal pneumonia	34% (6, 53)	High

159 *Study funded by industry

160 ** VE estimate presented as reported in study for overall estimate, all age groups, shortest time since vaccination (if stratified estimates

161 provided)

- 162 *** Cochrane Risk of Bias tool used to assess quality of evidence
- 163 VE= vaccine effectiveness; IPD=invasive pneumococcal disease; CAP= community-acquired pneumonia

DRAFT 10 August 2022

164 Vaccine-type invasive pneumococcal disease

165 PCV13

166	We identified four studies evaluating PCV13 efficacy or effectiveness against VT-IPD. Only one RCT was
167	identified, with a reported efficacy of 75% (95% CI: 41%, 91%) against VT-IPD in Dutch pneumococcal
168	vaccine-naïve, community-dwelling adults aged ≥65 years [5]. Vaccine effectiveness (VE) estimates from
169	three observational studies ranged from 47%–68% against VT-IPD in adults aged ≥65 years [32-34]
170	(Table 1). Lewis et al evaluated PCV13 VE in a cohort of U.S. adults aged ≥65 years who were enrolled in
171	Kaiser Permanente Northern California insurance and had not received PPSV23 before age 65 years.
172	PCV13 VE was 68% (95% CI: 38%, 84%) against all VT-IPD, and 53% (95% CI: -10%, 80%) against serotype
173	3 IPD; the study reported an increase in the incidence of IPD during the study period (2014–2018),
174	largely due to serotype 3. The other two observational studies by Pilishvili et al were case-control
175	studies that used Active Bacterial Core surveillance data to identify cases, but different sources to
176	identify controls [33, 34]. The VE estimate for PCV13 against IPD caused by PCV13 + 6C serotypes was
177	59% (95% CI: 11%, 81%) using controls identified from the commercial database ReferenceUSAGov
178	(InfoGroup) [33] and 47% (95% CI: 4%, 71%) using Medicare beneficiaries as controls; this estimate
179	increased to 67% (95% CI: 11%, 88%) when excluding serotype 3 IPD cases [34]. Due to overlap in cases
180	between the two Pilishvili et al studies, a pooled VE was not estimated between studies.
181	PPSV23
182	We did not identify any RCTs assessing PPSV23 efficacy against VT-IPD. Nine observational studies
183	reported VE among those who received PPSV23 within 5 years of the study assessment [24-26, 28, 31,
184	35-38]. Of these, seven were indirect cohorts and two were case-control studies. Studies evaluated VE
185	among adults aged \geq 60 years from Canada, Germany, United Kingdom (n=2), South Korea, Japan,
186	Taiwan, and Spain (n=2). Of note, Perniciaro et al reported a -30% (95% CI: -159%, 31%) PPSV23

187 effectiveness against VT-IPD; however, the authors observed that vaccination rates were low (16%)

- among adults who had received PPSV23 within five years prior to the study. Additionally, over 20% of
- 189 cases were caused by serotype 3. Therefore, we report the VE against PPSV23/non-PCV13 serotype IPD,
- 190 which was 35% (95% CI: -14%, 65%) [38]. The pooled VE estimate from these nine observational studies
- 191 was 45% (95% CI: 37%, 51%; I²=0%) (Figure 2).When limited to three studies in adults without
- immunocompromising conditions [24, 25, 28], the pooled VE estimate was 60% (95% CI: 47%, 69%; I²=
- 193 0%) (Figure 3). The pooled VE estimate for a sub-analysis restricting to adults aged 65 through 74 years
- 194 [24, 25, 31] was 52% (95% CI: 36%, 64%; I²= 5.2%) (Figure 4).
- 195 Figure 2. Pooled Vaccine Effectiveness Estimate of 23-Valent Pneumococcal Polysaccharide Vaccine
- 196 Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged ≥ 60 Years: Observational
- 197 studies, <5 years since vaccination
- 198 Figure 3. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against
- 199 Vaccine-Type Invasive Pneumococcal Disease in Healthy Adults: Observational studies, <5 years since
- 200 vaccination
- 201 Figure 4. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against
- 202 Vaccine-Type Invasive Pneumococcal Disease in Adults Aged 65–74 years: Observational studies, <5
- 203 years since vaccination
- 204 Vaccine-type Pneumococcal Pneumonia
- 205 PCV13
- 206 We identified four studies evaluating PCV13 efficacy or effectiveness against VT-pneumococcal
- 207 pneumonia. One RCT, among Dutch adults aged ≥65 years, reported an efficacy of 45% (95% CI: 14%,
- 208 65%) against the first episode of VT-nonbacteremic and noninvasive pneumococcal pneumonia [5]. In
- addition to the RCT, we identified three test-negative design (TND) observational studies for PCV13. The
- study by Prato et al was conducted among outpatient and inpatient Italian adults aged ≥65 years living
- in the Apulia region [39]. Many participants had one or more underlying comorbidity including chronic
- heart disease (53%), chronic respiratory disease (44%), and diabetes (25%). Patients were considered to
- have pneumococcal pneumonia if they had a positive PCR result for *S. pneumoniae* from blood, sputum,

DRAFT 10 August 2022

214	or bronchoalveolar-lavage. Prato et al reported a crude VE of 38% (95% CI: -132%, 89%) against VT-
215	pneumococcal pneumonia, and an adjusted VE was not reported [39]. The study by McLaughlin et al was
216	conducted as a nested study within a larger population-based surveillance study of U.S. adults in
217	Kentucky. Adults aged ≥65 years hospitalized with community acquired pneumonia (CAP) were
218	considered for enrollment. Most participants (88%) had one or more at-risk (defined as
219	immunocompetent, but presence of a chronic disease such as congestive heart failure, diabetes
220	mellitus, or liver disease) or high-risk (defined as immunocompromised) condition, and almost half of
221	participants were considered high-risk (46%). The adjusted VE was 68% (95% CI: -6%, 90%) against
222	nonbacteremic VT-pneumococcal pneumonia [40]. Heo et al evaluated the effectiveness of PCV13,
223	PPSV23, and sequential PCV13/PPSV23 vaccination against pneumococcal pneumonia among older
224	South Korean adults aged \geq 65 years hospitalized with CAP. The mean age of participants was 76.7 ± 6.9
225	years and many participants had \geq 1 underlying comorbidity (80%) or \geq 2 underlying comorbidities (45%).
226	The adjusted VE against VT-pneumococcal pneumonia was 41% (95% CI: -104%, 83%) for all adults aged
227	≥65 years, [30]. Pooled VE of the TND observational studies was not estimated since Prato et al only
228	reported a crude VE estimate.

229 PPSV23

We did not identify any RCTs evaluating efficacy of PPSV23 against VT-pneumococcal pneumonia. We
identified five observational studies with VE estimates ranging from −2% to 46% [29-31, 41, 42]. The
study by Kim et al was a hospital-based case-control study conducted among South Korean adults aged
≥65 years. The median age of the study population was 76 years and many participants had one or more
underlying medical conditions such as chronic pulmonary disease (37% of cases, 23% of controls) or
diabetes mellitus (24% of cases, 30% of controls). Approximately 26% of cases and 37% of controls had
an immunocompromising condition. The adjusted VE against VT-nonbacteremic pneumococcal

DRAFT 10 August 2022

237	pneumonia was -2% (95% CI: -40%, 26%) [31]. The four remaining observational studies were TND.
238	Lawrence et al used a nested TND of a prospective cohort study of adults aged ≥16 years hospitalized
239	with CAP at two hospitals in England. The mean age was similar between cases and controls (66.5 versus
240	65.4 years). The most common comorbidities among cases and controls were chronic obstructive
241	pulmonary disease (COPD) (24% for cases and controls), chronic lung disease (27% for cases and
242	controls), and hypertension (24% of cases, 25% of controls). The adjusted VE of PPSV23 against VT-
243	pneumococcal pneumonia (non-bacteremic and bacteremic) among those vaccinated <5 years was –7%
244	(95% CI: -54%, 26%). Lawrence et al observed that serotype 5 caused the largest proportion of cases of
245	PPSV23 serotype pneumonia <5 years since vaccination and considered the potential cross-reactivity
246	with other streptococcal strains that express serotype 5; however, the authors noted the potential
247	cross-reactivity did not alone explain the difference in effects among vaccinated and unvaccinated
248	patients. Therefore, we report the VE against PPSV23/non-PCV13 serotypes pneumococcal pneumonia,
249	which was 46% (95% CI: 5%, 69%) [41]. Suzuki et al conducted a prospective TND study among adults
250	aged ≥65 years at four community-based hospitals in Japan. Presence of underlying medical conditions
251	was similar between cases and controls. The adjusted VE of PPSV23 against VT-pneumococcal
252	pneumonia among outpatients and inpatients was 34% (95% CI: 6%, 53%) [29]. Heo et al, described
253	above, reported an adjusted VE of 6% (95% CI: -74%, 50%) against VT-pneumococcal pneumonia among
254	participants aged ≥65 years [30]. Chandler et al conducted a TND study among hospitalized CAP patients
255	identified through the University of Louisville Pneumonia Study database that was also used for the
256	study by McLaughlin et al [40]. The median age of vaccinated patients was 68 years, compared to 65
257	years among non-vaccinated patients. Vaccinated patients were more likely to have comorbid
258	conditions such as COPD (58% among vaccinated patients versus 47% among unvaccinated patients),
259	renal failure (33% versus 26%), or diabetes (37% versus 31%). Chandler et al reported 2% (95% CI: -52%,
260	37%) vaccine effectiveness against VT-pneumococcal pneumonia in adults aged ≥65 years who received

DRAFT 10 August 2022

261	PPSV23 within 5 years of assessment. [42]. Pooled VE of PPSV23 against VT-pneumococcal pneumonia
262	from the five observational studies was 18% (95% CI: -4%, 35%; I ² =0%) (Figure 5). When limited to adults
263	aged 65 through 74 years, the pooled VE estimate from three studies [29-31] was 26% (95% CI: -6%,
264	49%; I ² =0%) (Figure 6).
265 266 267	Figure 5. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Pneumococcal Pneumonia in Adults aged ≥16 Years: Observational studies, <5 years since vaccination
268 269 270	Figure 6. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Pneumococcal Pneumonia in Adults Aged 65 – 74 Years: Observational studies, <5 years since vaccination
271	Quality of Evidence
272	The risk of bias for the one RCT [5] was low; therefore, the quality of evidence was high for this study.
273	Regarding observational studies, scores using the Newcastle-Ottawa scale ranged from 3 to 8 (out of 9)
274	for PCV13 studies; three studies were deemed high quality (score of 7 or 8). Prato et al scored 3 for lack
275	of information regarding selection of controls and exposure criteria as well as lack of controlling for
276	potential confounders; it was rated low for quality of evidence. For PPSV23 observational studies, eight
277	studies were deemed high quality (score of 7 to 8) [25, 26, 29-31, 37, 38, 42] and five were deemed
278	medium quality (score of 4 to 6) [24, 28, 35, 36, 41]. All studies that scored medium quality lacked
279	information regarding source of controls or ascertainment of exposure (i.e., how vaccination history was
280	obtained).
281	Discussion
282	Recent data continue to support that both PCV13 and PPSV23 are effective against VT-IPD in adults.
283	However, there are a few differences in the published studies that warrant additional discussion. When

- 284 considering PCV13, the VE estimates from Pilishvili et al were lower than the estimates from the RCT;
- 285 this is expected, as effectiveness estimates from observational studies are often lower than efficacy

DRAFT 10 August 2022

286	estimates from clinical trials, which occur in a more controlled setting. Furthermore, the lower observed
287	estimates could be due to differences in the study population. Specifically, 54–60% of cases and 31–32%
288	of controls in the case-control studies by Pilishvili et al had immunocompromising conditions, whereas
289	adults with immunocompromising conditions at enrollment were not included in the RCT. Regarding
290	PCV13 effectiveness against VT-pneumococcal pneumonia, findings from observational studies
291	supported findings from the RCT, which showed 45% effectiveness. However, estimates from the
292	observational studies had wide confidence intervals.
293	When considering PPSV23, the pooled VE estimate for PPSV23 against VT-IPD was slightly lower than
294	what was observed for PCV13, even after limiting the data to <5 years since vaccination. These findings
295	are not unexpected as immunogenicity studies have observed polysaccharide vaccines to be less
296	immunogenic compared to conjugate vaccines. This review reinforced the existing evidence for PPSV23
297	effectiveness against VT-IPD.
298	Until recently, there were limited data specifically assessing PPSV23 VE against VT-pneumococcal
299	pneumonia. Previous studies that reported PPSV23 effectiveness against pneumococcal pneumonia or
300	CAP had variable results [43-45]. A review and meta-analysis by Falkenhorst et al estimated a pooled VE
301	against pneumococcal pneumonia of 64% (95%CI: 35– 80%) in clinical trials and 48% (95%CI: 25–63%) in
302	cohort studies, after excluding studies with high risk of bias [43]. Conversely, a review by Schiffner-Rohe
303	et al reported that three of four studies showed no efficacy against pneumococcal pneumonia [44].
304	Recent studies assessing PPSV23 effectiveness against VT-pneumococcal pneumonia allowed us to
305	conduct a pooled VE estimate, which suggests that PPSV23 provides some protection against VT-
306	pneumonia within 5 years of vaccination.

In October 2021, based in part on this analysis, the U.S. ACIP voted to recommend PCV15 in series with
 PPSV23 or PCV20 use in U.S. adults who have not previously received a PCV [9]. This recommendation

309	simplified previous recommendations on pneumococcal vaccine use in adults, which differed by age-
310	and risk-groups [6]. The new recommendations also provide an opportunity for broader PCV coverage
311	among adults compared to previous recommendations, in which routine PCV use was only
312	recommended for adults with immunocompromising conditions. Because licensure of PCV15 and PCV20
313	was based on immunogenicity and safety data only, there are remaining questions regarding clinical
314	implications of implementing these vaccines. For example, in clinical trials, PCV20 elicited slightly lower
315	immune responses compared with PCV13 for the 13 shared serotypes, although noninferiority criteria
316	were met [13]. The clinical implications of these findings, especially in adults with immunocompromising
317	conditions who were not included in Phase II and III trials, are unknown. Furthermore, it is unknown
318	whether PCV15 use in series with PPSV23 will provide better protection against the 15 shared serotypes
319	compared to PCV20 only. A study from Korea reported that among adults aged 65 through 74 years,
320	PCV13 in series with PPSV23 might result in improved protection against non-bacteremic VT-
321	pneumococcal pneumonia compared with PCV13 or PPSV23 alone [30].
321 322	pneumococcal pneumonia compared with PCV13 or PPSV23 alone [30]. There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that
322	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that
322 323	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous
322 323 324	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous evidence of vaccine efficacy. However, we identified several observational studies evaluating both
322 323 324 325	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous evidence of vaccine efficacy. However, we identified several observational studies evaluating both PCV13 and PPSV23 effectiveness against VT-IPD and VT-pneumonia. Heterogeneity in study populations,
322 323 324 325 326	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous evidence of vaccine efficacy. However, we identified several observational studies evaluating both PCV13 and PPSV23 effectiveness against VT-IPD and VT-pneumonia. Heterogeneity in study populations, e.g., different age distributions and different proportions of people with underlying conditions included,
322 323 324 325 326 327	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous evidence of vaccine efficacy. However, we identified several observational studies evaluating both PCV13 and PPSV23 effectiveness against VT-IPD and VT-pneumonia. Heterogeneity in study populations, e.g., different age distributions and different proportions of people with underlying conditions included, for PCV13 and PPSV23 studies may have affected the VE estimates. Furthermore, these differences in
 322 323 324 325 326 327 328 	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous evidence of vaccine efficacy. However, we identified several observational studies evaluating both PCV13 and PPSV23 effectiveness against VT-IPD and VT-pneumonia. Heterogeneity in study populations, e.g., different age distributions and different proportions of people with underlying conditions included, for PCV13 and PPSV23 studies may have affected the VE estimates. Furthermore, these differences in populations may in part contribute to the range of results observed across studies, though we have
322 323 324 325 326 327 328 329	There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous evidence of vaccine efficacy. However, we identified several observational studies evaluating both PCV13 and PPSV23 effectiveness against VT-IPD and VT-pneumonia. Heterogeneity in study populations, e.g., different age distributions and different proportions of people with underlying conditions included, for PCV13 and PPSV23 studies may have affected the VE estimates. Furthermore, these differences in populations may in part contribute to the range of results observed across studies, though we have attempted to address this limitation by conducting stratified analysis of the data. Despite these

- 333 In conclusion, our review showed that PCV13 and PPSV23 are both effective against VT-IPD and VT-
- pneumococcal pneumonia in adults. These data helped inform decisions on PCV15 and PCV20 use in
- adults in the United States, which currently do not have efficacy or effectiveness data against clinical
- 336 outcomes and could be used to inform similar decision in other countries. Post-licensure effectiveness
- and impact studies of PCV15 and PCV20 on pneumococcal disease in adults are needed to assess the
- 338 impact of the new recommendations.

DRAFT 10 August 2022

340 References

- 1. Gierke R, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison L, et al. 1299. Epidemiology
- of Invasive Pneumococcal Disease (IPD) in the United States 2011-2019. Open Forum Infectious
- 343 Diseases. 2021;8(Supplement_1):S737-S8.
- 344 2. Isturiz R, Grant L, Gray S, Alexander-Parrish R, Jiang Q, Jodar L, et al. Expanded Analysis of 20
- 345 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia
- in Hospitalized US Adults. Clin Infect Dis. 2021;73(7):1216-22.
- 347 3. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide
- 348 vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee
- on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-9.
- 4. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent
- 351 pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults
- aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR
- 353 Morb Mortal Wkly Rep. 2014;63(37):822-5.
- 354 5. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide
- conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25.
- 356 6. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent
- 357 Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults
- Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
- 359 MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-75.
- 360 7. Food and Drug Administration. VAXNEUVANCE 2021 [Available from:
- 361 <u>https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance</u>.
- 362 8. Food and Drug Administration. PREVNAR 20 2021 [Available from:
- 363 <u>https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20</u>.

DRAFT 10 August 2022

364	9.	Kobayashi M, Fa	rrar JL, Gierke R,	Britton A, Childs L,	Leidner AJ, et al.	Use of 15-Valent
-----	----	-----------------	--------------------	----------------------	--------------------	------------------

365 Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults:

- 366 Updated Recommendations of the Advisory Committee on Immunization Practices United States, 2022.
- 367 MMWR Morb Mortal Wkly Rep. 2022;71(4):109-17.
- 368 10. Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, et al. Safety and
- 369 immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults
- 370 ≥50 years of age. Vaccine. 2018;36(45):6875-82.

11. Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, et al. Safety and immunogenicity

- of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine
- in adults \geq 65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
- Human Vaccines and Immunotherapeutics. 2019;15(3):540-8.
- 12. Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, et al. A phase 3 trial of
- 376 safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared
- 377 with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
- 378 Vaccine. 2022;40(1):162-72.
- 13. Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 Randomized Clinical
- 380 Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in
- 381 Adults 18 Years and Older. Clin Infect Dis. 2021.
- 14. Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, Tolerability, and
- 383 Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of
- 384 Age. Clin Infect Dis. 2020.
- 385 15. Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Rajender Reddy K, et al.
- 386 Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in

DRAFT 10 August 2022

387	Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A			
388	Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis. 2022;9(3):ofab605.			
389	16. Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, et al. Safety and			
390	immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. Aids.			
391	2022;36(3):373-82.			
392	17. Berild JD, Winje BA, Vestrheim DF, Slotved HC, Valentiner-Branth P, Roth A, et al. A Systematic			
393	Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal			
394	Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population. Pathogens.			
395	2020;9(4).			
396	18. Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia2021.			
397	19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA			
398	statement for reporting systematic reviews and meta-analyses of studies that evaluate health care			
399	interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.			
400	20. Innovation VH. Covidence Systematic Review software.			
401	21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane			
402	Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.			
403	22. Wells G, Shea B, O'Connell D, Peterson j, Welch V, Losos M, et al. The Newcastle–Ottawa Scale			
404	(NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis 2000; .			
405	23. Borenstein M, Hedges, L., Higgins, J., & Rothstein, H. Comprehensive Meta-Analysis Version 3.			
406	Englewood, NJ Biostat; 2013.			
407	24. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent			
408	pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England			
409	and Wales. Vaccine. 2012;30(48):6802-8.			

DRAFT 10 August 2022

410	25. Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et al. Effectiveness of 23-
411	Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence
412	from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine. 2018;6:42-50.
413	26. Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba
414	Deorador E, Lasheras Carbajo MD, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine
415	in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011. Euro Surveill.
416	2014;19(40):20922.
417	27. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E,
418	Raga-Luria X, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against
419	community-acquired pneumonia in the general population aged >/= 60 years: 3 years of follow-up in the
420	CAPAMIS study. Clin Infect Dis. 2014;58(7):909-17.
421	28. Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal vaccination
422	programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine.
423	2013;31(49):5863-71.
424	29. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific
425	effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in
426	adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis.
427	2017;17(3):313-21.
428	30. Heo JY, Seo YB, Choi WS, Kim EJ, Jeong HW, Lee J, et al. Effectiveness of Pneumococcal
429	Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-
430	Negative Study. J Infect Dis. 2022;225(5):836-45.
431	31. Kim JH, Chun BC, Song JY, Kim HY, Bae IG, Kim DM, et al. Direct effectiveness of pneumococcal
432	polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal

- 433 pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
- 434 Vaccine. 2019;37(21):2797-804.
- 435 32. Lewis N, Hsiao A, Hansen J, Yee A, Chao C, Suaya JA, et al. Effectiveness of 13-valent
- 436 pneumococcal conjugate vaccine against invasive pneumococcal disease in older adults. Open Forum
- 437 Infectious Diseases. 2019;6 (Supplement 2):S953-S4.
- 438 33. Pilishvili T, Almendares O, Xing W, Farley MM, Schaffner W, Thomas A, et al. Effectiveness of
- 439 Pneumococcal Vaccines against Invasive Pneumococcal Disease (IPD) among Adults >=65 Years Old in
- the United States. Melbourne, Australia2018.
- 441 34. Pilishvili T, Almendares OM, Nanduri S, Warnock R, Wu X, McKean S, et al. Evaluation of
- 442 pneumococcal vaccine effectiveness against invasive pneumococcal disease among us medicare
- 443 beneficiaries >=65 years old. Open Forum Infectious Diseases. 2018;5 (Supplement 1):S10-S1.
- 444 35. Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P. Effectiveness of Pneumococcal
- 445 Vaccination for Elderly People in Catalonia, Spain: A Case-control Study. Clin Inf Dis. 2005;40:1250-57.
- 446 36. Shimbashi R, Suzuki M, Chang B, Watanabe H, Tanabe Y, Kuronuma K, et al. Effectiveness of 23-
- 447 valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan,
- 448 2013-2017. Emerging Infectious Diseases. 2020;26(10):2378-86.
- 449 37. Su WJ, Chuang PH, Chang LY, Lo HY, Chiang CS, Wang ET, et al. Application of the screening and
- 450 indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75
- 451 years and older in Taiwan. BMC Infectious Diseases. 2021;21(1):45.
- 452 38. Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older
- 453 adults with invasive pneumococcal disease in Germany: A retrospective cohort study. The Lancet
- 454 Regional Health Europe. 2021;7:100126.

DRAFT 10 August 2022

455	39.	Prato R, Fortunato F, Cappelli MG, Chironna M, Martinelli D. Effectiveness of the 13-val	ent

456 pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year

457 prospective cohort. BMJ Open. 2018;8(3):e019034.

- 458 40. McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, et al. Effectiveness of 13-
- 459 Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in

460 Older US Adults: A Test-Negative Design. Clinical Infectious Diseases. 2018;67(10):1498-506.

461 41. Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, et al. Effectiveness of the 23-

462 valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in

- 463 adults: A case-control test-negative design study. PLoS Medicine / Public Library of Science.
- 464 2020;17(10):e1003326.
- 465 42. Chandler T, Furmanek S, Carrico R, Balcom D, Arnold F, Ramirez J. 23-Valent Pneumococcal

466 Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to

467 Vaccine-Type Streptococcus pneumoniae. Microorganisms. 2022;10(3).

468 43. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C.

469 Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal

470 Disease in the Elderly: Systematic Review and Meta-Analysis. PLOS ONE. 2017;12(1):e0169368.

471 44. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus F-W. Efficacy of PPV23 in Preventing

472 Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis. PLOS

473 ONE. 2016;11(1):e0146338.

474 45. Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et al. Effectiveness of

475 pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of

476 observational studies. PLoS One. 2017;12(5):e0177985.

Database	Strategy
Medline	1. streptococcus pneumoniae/
(OVID)	2. (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae").tw,kf.
	3. 1 or 2
	4. vaccination/ or immunization/ or Vaccines, Conjugate/
	5. (vaccine? or vaccination? or immunisation or immunization).tw,kf.
	6. 4 or 5
	7. Pneumococcal Vaccines/
	8. (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or
	"pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or
	"23valent").tw,kf.
	9. 7 or 8
	10. (3 and 6)
	11. 10 or 9
	12. comparative effectiveness research/ or treatment outcome/ or Vaccine Potency/
	13. (efficacy or effectiveness or effects or "immune response" or impact or "treatment
	outcome").tw,kf.
	14. 12 or 13
	15. adult/ or aged/ or "aged, 80 and over"/ or frail elderly/

	16. (adult? or elderly or elderlies).tw,kf.
	17. 15 or 16
	18. 11 and 14 and 17
	19. (201904* OR 201905* OR 201906* OR 201907* OR 201908* OR 201909* OR 201910* OR
	201911* OR 201912* OR 2020* OR 2021*).ed,ep,yr,dp,dt.
	20. 17 and 18
F - L	
Embase	1. Streptococcus pneumoniae/
(OVID)	2. (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s
1988-	pneumoniae").tw,kw.
	3. 1 or 2
	4. vaccination/ or immunization/ or vaccine/
	5. (vaccine? or vaccination? or immunisation or immunization).tw,kw.
	6. 4 or 5
	7. Pneumococcus vaccine/
	8. (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or
	"pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or
	"23valent").tw,kw.
	9. 7 or 8
	10. 3 and 6
	"23valent").tw,kw. 9. 7 or 8

	11. 9 OR 10										
	12. comparative effectiveness/ or treatment outcome/										
	13. (efficacy or effectiveness or effects or "immune response" or impact or "treatment										
	outcome").tw,kw.										
	14. 12 or 13										
	15. aged/ or adult/ or aged hospital patient/ or frail elderly/ or institutionalized elderly/ or very elderly/										
	16. (adult? or elderly or elderlies).tw,kw.										
	17. 15 or 16										
	18. 11 and 14 and 17										
	19. (201904* OR 201905* OR 201906* OR 201907* OR 201908* OR 201909* OR 201910*										
	201911* OR 201912* OR 2020* OR 2021*).dc										
	20. limit 19 to (conference abstracts or embase)										
Cochrane	(
Library											
	(pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s										
	pneumoniae"):ti,ab										
	AND										
	([mh Vaccines] OR [mh Immunization] OR (vaccine# or vaccination# or immunisation or										
	immunization):ti,ab)										
)										

	OR
	(MH "Pneumococcal Vaccine") OR TI (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent") OR AB (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23 valent" or "23valent")
	AND [mh "Treatment Outcomes"] OR (efficacy or effectiveness or effects or "immune response" or impact or "treatment outcome"):ti,ab
	AND
	[mh Adult] OR [mh Aged+] OR (adult# or elderly or elderlies):ti,ab
CINAHL	(
(EbscoHost)	(TI (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae") OR AB (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae")) AND ((MH "Vaccines") OR (MH "Immunization") OR TI (vaccine# or vaccination# or immunisation or immunization) OR AB (vaccine# or vaccination# or immunisation or immunization))


DRAFT 10 August 2022

OR

	(MH "Pneumococcal Vaccine") OR TI (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or									
	"10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or									
	ppv23 or "ppv 23" or "23 valent" or "23 valent") OR AB (heptavalent or "7 valent" or "7 valent" or									
	"pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or									
	pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent")									
)									
	AND									
	(MH "Treatment Outcomes") OR TI (efficacy or effectiveness or effects or "immune response" or									
	impact or "treatment outcome") OR AB (efficacy or effectiveness or effects or "immune response" or									
	impact or "treatment outcome")									
	AND									
	((MH "Adult") OR (MH "Aged+") OR TI (adult# or elderly or elderlies) OR AB (adult# or elderly or									
	elderlies))									
	Limiters - Published Date: 20190401-20210218; Exclude MEDLINE records									
Scopus	(TITLE-ABS-KEY("heptavalent" or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or									
(for WOS)	"10valent" or "pcv10" or "pcv 10" or "13valent" or "13 valent" or "pcv13" or "pcv 13" or "ppv23" or									
	"ppv 23" or "23 valent" or "23 valent") OR (TITLE-ABS-KEY("vaccine\$" or "vaccination\$" or									
	"immunisation" or "immunization") AND TITLE-ABS-KEY("pneumococcal" or "pneumococci" or									
	"streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae"))) AND TITLE-ABS-									

KEY("adult\$" or "elderly" or "elderlies") AND TITLE-ABS-KEY("efficacy" or "effectiveness" or
"effects" or "immune response" or "impact" or "treatment outcome")
Limit April 2019 -
Search 1:
(pneumococcal OR pneumococci OR "streptococcus pneumonie" OR "streptococcus pneumoniae" OR "s pneumoniae") AND (vaccine* OR vaccination* OR immunisation OR immunization) AND (efficacy OR effectiveness OR effects OR "immune response" OR impact OR "treatment outcome") AND (adult* OR elderly OR elderlies)
– limited to 2019-2021
Search 2:
(heptavalent OR "7 valent" OR "7valent" OR "pcv 7" OR pcv7* OR "10 valent" OR "10valent" OR pcv10 OR "pcv 10" OR "13valent" OR "13 valent" OR pcv13 OR "pcv 13" OR ppv23 OR "ppv 23" OR "23 valent" OR "23valent") AND (efficacy OR effectiveness OR effects OR "immune response" OR impact OR "treatment outcome") AND (adult* OR elderly OR elderlies) – limited to 2019-2021

Figure 1. PRISMA Study flow diagram



*Berild 2020 is the publication for the Norwegian Public Health Institute (NIPH) systematic review of literature on


pneumococcal vaccine effectiveness in adults conducted for the World Health Organization's Strategic Advisory Group of Experts.

Figure 1 - PRISMA flow diagram

Figure 2. Pooled Vaccine Effectiveness Estimate of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged ≥ 60 Years: Observational studies, <5 years since vaccination


Pooled Vaccine Effectiveness of PPSV23 against VT-IPD, all conditions

Study name	Subgroup within study	Time point	Outcome	Statistics for each study					
				Odds ratio	Lower limit	Upper limit	Z-Value	p-Value	
Dominguez 2005	>=05 years, all	1-2 years	VT-IPD	0.360	0.184	0.705	-2.980	0.003	
Gutierrez-Rodriguez 2014	>=60 years, all	<5 years	VT-IPD	0.555	0.382	0.805	-3.091	0.002	
Rudnick 2013	>=65 years, all	<5 years	VT-IPD	0.587	0.433	0.798	-3.430	0.001	
Shimbashi, 2020	>=65 years, all	<5 years	VT-IPD	0.608	0.378	0.979	-2.047	0.041	
Su, 2021	>=75 years, all	ect year	VT-IPD	0.263	0.113	0.611	-3.105	0.002	
Andrews, 2012	>=65 years, all	<2 years	VT-IPD	0.520	0.399	0.678	-4.831	0.000	
Djennad, 2018	>=65 years, all	<2 years	VT-IPD	0.590	0.455	0.763	-4.015	0.000	
Perniciaro, 2021	>=60 years, all	<2 years	PPV11-IPD	0.640	0.355	1,155	-1.481	0.138	
Kim, 2019	>+05 years, all	<5 years	VT-IPD	0.581	0.332	1.016	-1.905	0.057	
				0.551	0,485	0.626	-9.151	0.000	



Favors PPSV23 Favors No Vaccine

Figure 3. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Invasive Pneumococcal Disease in Healthy Adults: Observational studies, <5 years since vaccination



Pooled Vaccine Effectiveness of PPSV23 against VT-IPD, exclude IC, youngest age group



Figure 4. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged 65–74 years: Observational studies, <5 years since vaccination


Pooled Vaccine Effectiveness of PPSV23 against VT-IPD, limited to adults aged 65-74 years

Study name	tudy name Subgroup within study Time point			statistics for each study					Odds ratio and 95% CI					
				Odds ratio	Lower limit		Z-Value	p-Value						
Kim 2019	65-74 years, all	<5 years	VT-IPD	0.301	0.120	0.754	-2.584	0.010					1	
Andrews, 2	01265-74 years, all	<2 years	VT-IPD	0.420	0.265	0.667	-3.682	0.000		- I -				
Djennad, 2	01865-74 years, all	<2 years	VT-IPD	0.570	0.391	0.832	-2.917	0.004			- 1			
				0.478	0.358	0.639	-4.981	0.000			♦			
												40	100	
									0.01	0.1	1	10	100	



IP IP

Figure 5. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Pneumococcal Pneumonia in Adults aged ≥16 Years: Observational studies, <5 years since vaccination



Pooled Vaccine Effectiveness of PPSV23 against VT-Pneumococcal Pneumonia, <5 Years of Vaccination



10

P

P


P

100

IP/OP

Figure 6. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Pneumococcal Pneumonia in Adults Aged 65 – 74 Years: Observational studies, <5 years since vaccination

Pooled Vaccine Effectiveness of PPSV23 against VT-Pneumococcal Pneumonia, Age 65-74 Years



Favors PPSV23 Favors No Vaccine